Lupin Ltd

Lupin announced the completion of its acquisition of VISUfarma B.V. (VISUfarma), a leading European specialty pharmaceutical company focused on ophthalmology, from GHO Capital Partners LLP (GHO). The acquisition represents a significant milestone in Lupin's strategy to expand its specialty care portfolio and strengthen its presence in Europe. The integration of VISUfarma has significantly expanded Lupin's ophthalmology portfolio to over 60 branded products spanning dry eye, glaucoma, eyelid hygiene, blepharitis, retinal health, and specialty nutraceuticals. VISUfarma's strong commercial footprint across key European markets, including Italy, the UK, Spain, Germany, and France, is strengthened by a highly experienced team with deep ophthalmology expertise, trusted relationships, and strong local market insight. VISUfarma enhances Lupin's ability to address the growing global demand for innovative eye care solutions, driven by an ageing population and the growing burden of diabetes-related eye complications.

The approval covers strengths of 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) in single-dose vials, the company said in a statement. The product has been deemed bioequivalent to Merck & Co.'s Bridion Injection. It is indicated for the reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide in adults and pediatric patients aged two years and above undergoing surgery. Tentative approval indicates that the drug meets all regulatory requirements but cannot be marketed in the United States until the expiry of applicable exclusivities or patents. Lupin is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. It specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. The pharmaceutical company reported a 37.46% surge in consolidated net profit to Rs 1,175.55 crore in Q3 FY26 as against Rs 855.16 crore posted in Q3 FY25. Total revenue from operations jumped 24.26% year-on-year to Rs 7,167.52 crore in the quarter ended 31 December 2025.

The approval covers strengths of 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) in single-dose vials, the company said in a statement. The product has been deemed bioequivalent to Merck & Co.'s Bridion Injection. It is indicated for the reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide in adults and pediatric patients aged two years and above undergoing surgery. Tentative approval indicates that the drug meets all regulatory requirements but cannot be marketed in the United States until the expiry of applicable exclusivities or patents. Lupin is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. It specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. The pharmaceutical company reported a 37.46% surge in consolidated net profit to Rs 1,175.55 crore in Q3 FY26 as against Rs 855.16 crore posted in Q3 FY25. Total revenue from operations jumped 24.26% year-on-year to Rs 7,167.52 crore in the quarter ended 31 December 2025. The counter shed 0.95% to end at Rs 2,312.70 on the BSE. Powered by Capital Market - Live

Lupin announced that Multicare Pharmaceuticals Philippines, Inc. (MPPI), a subsidiary of Nanomi B.V., the Netherlands (Nanomi), which is a wholly owned subsidiary of the Company, has bought back 2,813,811 equity shares from some of its existing shareholders. Nanomi did not participate in the said buyback. This has resulted in increase in the shareholding of Nanomi in MPPI from 51% to 56.28% effective today.Powered by Capital Market - Live

Pitolisant is indicated for the treatment of excessive daytime sleepiness in patients suffering from narcolepsy, including adults and children aged six years and above. It is also used to treat cataplexy, sudden episodes of muscle weakness, in adults with narcolepsy. The drug belongs to a class known as H3 receptor antagonists and works by regulating neurotransmitters involved in sleep-wake cycles. The company stated that the approved product is bioequivalent to Wakix, as per the approved labeling by the U.S. regulator. The tablets will be manufactured at Lupin's facility in Nagpur, India. Lupin is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. It specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. The pharmaceutical company reported a 37.46% surge in consolidated net profit to Rs 1,175.55 crore in Q3 FY26 as against Rs 855.16 crore posted in Q3 FY25. Total revenue from operations jumped 24.26% year-on-year to Rs 7,167.52 crore in the quarter ended 31 December 2025. The counter rose 0.62% to Rs 2,346.25 on the BSE. Powered by Capital Market - Live

Lupin has received tentative approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application for Pitolisant Tablets, 4.45mg and 17.8mg. This product would be manufactured at Lupin's Nagpur facility in India. The U.S. FDA has tentatively approved Lupin's Pitolisant Tablets 4.45mg and 17.8 mg as bioequivalent to Wakix' for the indication in the approved labeling. Powered by Capital Market - Live

Lupin has allotted 135,892 equity shares under ESOP on 24 March 2026. With this allotment, the paid up equity share capital has increased to Rs 91,43,58,222 consisting of 45,71,79,111 equity shares of Rs 2/- each.Powered by Capital Market - Live

The move marks a significant step in scaling LMS's peptide building-blocks platform and CRDMO capabilities. The expanded infrastructure features a new block to enhance existing CRDMO operations, supported by dedicated peptide manufacturing capacity across two additional specialized units. These improvements will enable advanced development and flexible manufacturing, supporting complex therapeutics and meeting global demand for advanced pharmaceutical solutions. Dr. Abdelaziz Toumi, chief executive officer, Lupin Manufacturing Solutions, said, 'As pharmaceutical innovation increasingly shifts toward complex modalities, building deep capabilities and execution excellence has become critical. This expansion underscores our commitment to building advanced, scalable capabilities that support complex development programs and reinforce our role in the global peptide ecosystem, enabling meaningful partnerships with innovators worldwide.' With global drug development increasingly defined by molecular complexity, such as peptides and biologic ADCs, this expansion reinforces LMS's ability to consistently supply high-quality peptide building blocks, including protected amino acids. Lupin is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. It specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. The pharmaceutical company reported a 37.46% surge in consolidated net profit to Rs 1,175.55 crore in Q3 FY26 as against Rs 855.16 crore posted in Q3 FY25. Total revenue from operations jumped 24.26% year-on-year to Rs 7,167.52 crore in the quarter ended 31 December 2025. The counter slipped 1.12% to Rs 2,276.85 on the BSE. Powered by Capital Market - Live

Lupin Manufacturing Solutions (LMS), a global CRDMO and subsidiary of global pharma major Lupin, today announced a strategic expansion of its Dabhasa manufacturing facility, marking a significant step toward scaling its peptide building-blocks platform and CRDMO capabilities. The expanded infrastructure features a new block to enhance existing CRDMO capabilities supported by dedicated peptide manufacturing capacity across two additional specialized units. These upgrades will enable advanced development and flexible manufacturing, supporting complex therapeutics and meeting global demand for advanced pharmaceutical solutions. Powered by Capital Market - Live

The inspection was conducted between 2 March 2026 and 7 March 2026. Following the inspection, the US regulator issued Form 483, noting two observations at the facility. The company said it will address the observations and respond to the US FDA within the stipulated timeframe. Lupin added that it remains committed to compliance with Current Good Manufacturing Practice (CGMP) standards across all its facilities. Lupin is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. It specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. The pharmaceutical company reported a 37.46% surge in consolidated net profit to Rs 1,175.55 crore in Q3 FY26 as against Rs 855.16 crore posted in Q3 FY25. Total revenue from operations jumped 24.26% year-on-year to Rs 7,167.52 crore in the quarter ended 31 December 2025.Powered by Capital Market - Live